Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

StatusCompleted
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 2 entries Show 5 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Jul 31, 2026 to May 31, 2026
    • Enrollment target: estimated 80 to confirmed 78
    • Eligibility criteria expanded, about 18 words
    • Site details revised
  2. Re-verified, no change to tracked fieldsv13
  3. Primary and study completion dates: Jun 30, 2025 to Jul 31, 2026v12
  4. Re-verified, no change to tracked fieldsv11
  5. Primary and study completion dates: Jul 31, 2026 to Jun 30, 2025
    • Collaborators expanded, about 8 words
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary and study completion dates: Jul 31, 2024 to Jul 31, 2026v9
  2. Primary completion date: Jul 31, 2023 to Jul 31, 2024
    • Study completion date: Apr 30, 2024 to Jul 31, 2024
    v8
  3. Primary completion date: Jul 2023 to Jul 31, 2023
    • Study completion date: Apr 2024 to Apr 30, 2024
    • Start date changed from estimate of May 2022 to May 17, 2022
    v7
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v6
  5. Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v5
  6. Start date: Apr 2022 to May 2022v4
  7. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Sep 2025 to Jul 2023
    • Study completion date: Sep 2025 to Apr 2024
    • Start date: Mar 2022 to Apr 2022
    • Site details revised
  8. Start date: Feb 2022 to Mar 2022v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yale University
490 trials monitored
See 31 trials at risk
The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
Trial Details
NCT Number NCT05203965
Lead Sponsor Yale University
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions
(from sponsor)		 Familial Alcoholism Vulnerability
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov